3724-26-3

Usage

Uses

Used in Pharmaceutical Synthesis:
(1H-IMIDAZOL-2-YL)-METHANOL is used as a building block for the synthesis of pharmaceuticals, leveraging its versatile reactivity to contribute to the development of new drugs and medicinal compounds.
Used in Organic Compounds Synthesis:
In the realm of organic chemistry, (1H-IMIDAZOL-2-YL)-METHANOL serves as a key component in the synthesis of various organic compounds, enhancing the range of possible chemical reactions and products.
Used in Coordination Chemistry as a Ligand:
(1H-IMIDAZOL-2-YL)-METHANOL is utilized as a ligand in coordination chemistry, forming complexes with metal ions. This application is instrumental in material science and chemical research for creating new materials with specific properties.
Used in Medicine:
Owing to its potential applications in medicine, (1H-IMIDAZOL-2-YL)-METHANOL is employed in the development of pharmaceuticals, where its unique properties can be harnessed to address various medical needs.
Used in Materials Science:
In the field of materials science, (1H-IMIDAZOL-2-YL)-METHANOL contributes to the advancement of new materials through its role in the synthesis process and its ability to form complexes with metal ions, thereby influencing the properties of the resulting materials.
Used in Chemical Research:
(1H-IMIDAZOL-2-YL)-METHANOL is also used in chemical research to explore its reactivity and stability, further expanding the understanding of its potential applications and the development of new chemical processes.

Upstream product

• 10111-08-7 2-imidazolecarbaldehyde 
• 935862-80-9 2-(hydroxymethyl)-N,N-dimethyl-1H-imidazole-1-sulfonamide 
• 288-32-4 1H-imidazole 
• 50-00-0 formaldehyd 
• 5376-10-3 1-benzyl-2-(hydroxymethyl)imidazole 

Downstream Products

• 540510-47-2 1-(4-amino-3-fluorophenyl)-2-hydroxymethylimidazole 
• 14488-04-1 2-(2'-imidazolyl)benzimidazole 
• 2939-05-1 2-(bromomethyl)-1H-imidazole hydrobromide 
• 40403-72-3 2-imidazolylmethyl chloride 
• 17392-83-5 (R)-Methyl lactate 
• 1454336-61-8 (S)-(1H-imidazol-2-yl)methyl 2-hydroxypropanoate 

Relevant academic research and scientific papers

Retention mechanism of imidazoles in connective tissue. III. Aldehyde adduct formation of a 4(5H)(or 5(4H))-imidazolone product in vitro

2-Methylimidazole (2MI), as well as imidazole, has been thought to undergo cupro-ascorbate (Cu-VC)-catalyzed oxidative transformation in vitro to become a reactive species capable of combining with aldehydes intrinsic to connective-tissue proteins. We attempted to seize the essence of the above reaction through obtaining the structural information of an aldehyde-bonding species. As major products from 2MI in the in vitro Cu-VC system, 2- hydroxymethylimidazole (2(OH)MI) and 2-methyl-4(SH)(or 5(4H))-imidazolone (2MIone) were identified by mass-spectral and chromatographic comparison with the corresponding authentic standards synthesized. The in situ addition of acetaldehyde or propionaldehyde as a simple protein-aldehyde model to the system resulted in the deducible formation of an aldol condensate, 2-methyl- 4(or 5)-ethylidene-4(SH)(or 5(4H))-imidazolone (2MEIone) or its possible analogue with a propylidene moiety, respectively. The authentic compound of 2MIone directly reacted with acetaldehyde and easily afforded the products assignable to the isomers of 2MEIone through the ethylidene moiety at physiological pH and temperature, whereas neither 2MI or 2(OH)MI reacted at all. These results suggest that a 4(SH)(or 5(4H))-imidazolone product, although simply a monooxygenated form, is sufficiently reactive to give aldol condensation-typed covalent adducts with aldehydes, even under physiological conditions, probably having an activated methylene moiety in the ring structure. Based on the present results, we discussed the mechanism of the retention of imidazole-containing drugs in connective tissue.

Crystal Structure and Subsequent Ligand Design of a Nonriboside Partial Agonist Bound to the Adenosine A2AReceptor

In this study, we determined the crystal structure of an engineered human adenosine A2A receptor bound to a partial agonist and compared it to structures cocrystallized with either a full agonist or an antagonist/inverse agonist. The interaction between the partial agonist, belonging to a class of dicyanopyridines, and amino acids in the ligand binding pocket inspired us to develop a small library of derivatives and assess their affinity in radioligand binding studies and potency and intrinsic activity in a functional, label-free, intact cell assay. It appeared that some of the derivatives retained the partial agonist profile, whereas other ligands turned into inverse agonists. We rationalized this remarkable behavior with additional computational docking studies.

Chemoselective transfer hydrogenation of aromatic and heterocyclic aldehydes by green chemically prepared cobalt oxide nanoparticles

A new surfactant (quercetin) assisted hydrothermal method is used for the preparation of phase pure cobalt oxide (Co3O4) nanoparticles (Nps). The quercetin acted well as surfactant in producing size controlled Nps. The produced Nps were extensively characterized by various techniques to reveal its chemical composition, structure, morphology, size and thermal behavior. The main objective of the study is to employ the prepared material as heterogeneous catalyst for hydrogenation of therapeutically important aldehydes. The capability of the catalyst is appear to be good, since the yield of alcohols from structurally different aldehydes is adequate with short period of time. Also the catalyst is recyclable, stable, no need of addition of ligands for activation and environmentally benign.

3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted- 2/-/-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, e

Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

Bare histidine-serine models: Implication and impact of hydrogen bonding on nucleophilicity

A new family of 2-hydroxyalk(en/yn)ylimidazoles has been evaluated as serine-histidine bare dyad models for the ring-opening reaction of L-lacOCA, a cyclic O-carboxyanhydride. These models were selected to unravel the implication of intramolecular hydrogen bonding and to substantiate its influence on the nucleophilicity of the alcohol moiety, as it is suspected to occur in enzyme active sites. Although designed to exclusively facilitate the preliminary step of proton transfer during the studied ring-opening reaction, these minimalistic models depicted a measureable increase in reactivity relative to the isolated fragments. A couple of reliable experimental and theoretical methods have been developed to readily monitor the strength of the intramolecular hydrogen bond in dilute solution. Results show that the folded conformers are the most nucleophilic species because of the intramolecular hydrogen bond. Copyright

Non-benzimidazole containing inhibitors of respiratory syncytial virus

Several non-benzimidazole containing inhibitors of respiratory syncytial virus are described. Core template modification, analysis of antiviral activity, physicochemistry and optimisation of properties led to the thiazole-imidazole 13, that showed a good potency and pharmacokinetic profile in the rat.

Antibacterial activity of aminals and hemiaminals of pyrazole and imidazole

Antibacterial activity of 1,1'-methylenedipyrazole (AM1), 1-hydroxymethylpyrazole (SAM1), 1,1'-methylenediimidazole (AM2), and 1-hydroxymethylimidazole (SAM2) has been tested against reference and clinical strains by both difusimetric and broth dilution methods. Overall, the minimal inhibitory concentrations of tested compounds ranged from 180 to 270 μg/ml, while the minimal bactericidal concentrations were between 360 and 720 μg/ml. Comparative assessment with phenol and formaldehyde shows that AM1, AM2, SAM1, and SAM2 have moderate to good antibacterial activity.

Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities

The pyrrole based N6022 was recently identified as a potent, selective, reversible, and efficacious S-nitrosoglutathione reductase (GSNOR) inhibitor and is currently undergoing clinical development for the treatment of acute asthma. GSNOR is a member of the alcohol dehydrogenase family (ADH) and regulates the levels of S-nitrosothiols (SNOs) through catabolism of S-nitrosoglutathione (GSNO). Reduced levels of GSNO, as well as other nitrosothiols (SNOs), have been implicated in the pathogenesis of many diseases including those of the respiratory, cardiovascular, and gastrointestinal systems. Preservation of endogenous SNOs through GSNOR inhibition presents a novel therapeutic approach with broad applicability. We describe here the synthesis and structure-activity relationships (SAR) of novel pyrrole based analogues of N6022 focusing on removal of cytochrome P450 inhibition activities. We identified potent and novel GSNOR inhibitors having reduced CYP inhibition activities and demonstrated efficacy in a mouse ovalbumin (OVA) model of asthma.

NMR characterization of hydrate and aldehyde forms of imidazole-2- carboxaldehyde and derivatives

The existence and stability of the aldehyde-hydrate form of imidazole-2-carboxaldehyde (4) were studied using FTIR together with solution- and solid-state NMR experiments. The results allowed us to conclude that the hydrate form was stable and precipitate